H. Lundbeck A/S
http://www.lundbeck.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From H. Lundbeck A/S
Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.
AbbVie Ready To Leverage Migraine Franchise In Crowded Market
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
Finance Watch: Two New VC Funds Raise $955m To Back Life Science Companies
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Deal Watch: Lilly Teams Up With Lycia In Protein Degradation
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abide Therapeutics Inc.
- Alder Biopharmaceuticals, Inc.
- Chelsea Therapeutics International, Ltd.
- Lundbeck La Jolla Research Center
- Lundbeck Seattle Biopharmaceuticals
- Ovation Pharmaceuticals, Inc
- Saegis Pharmaceuticals, Inc.